NASDAQ:CSBR

Champions Oncology Q4 2026 Earnings Report

Champions Oncology logo
$6.25 -0.57 (-8.42%)
As of 04:00 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Champions Oncology EPS Results

Actual EPS
N/A
Consensus EPS
-$0.05
Beat/Miss
N/A
One Year Ago EPS
N/A

Champions Oncology Revenue Results

Actual Revenue
N/A
Expected Revenue
$12.89 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Champions Oncology Announcement Details

Quarter
Q4 2026
Time
After Market Closes
Conference Call Date
Wednesday, July 22, 2026
Conference Call Time
4:30PM ET

Conference Call Resources

Champions Oncology Earnings Headlines

Rickards Predicts: Trump to buy tiny $2 stock?
Jim Rickards believes the Trump administration is about to take a direct stake in a $2 stock sitting on the largest mineral reserve in the country - enough gold for a new Fort Knox, enough copper to rebuild the U.S. electric grid 25 times over. The Trump administration has previously staked positions in MP Materials, Lithium America, Trilogy Metals, and USA Rare Earth - each time shares moved higher. A landmark policy decision expected before June 30 could reprice this stock from $2 to $20 or more within a year.tc pixel
See More Champions Oncology Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Champions Oncology? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Champions Oncology and other key companies, straight to your email.

About Champions Oncology

Champions Oncology (NASDAQ:CSBR) engages in the development and sale of technology solutions and products to personalize the development and use of oncology drugs. Its technology platform, TumorGraft, is a novel approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. It uses its technology to offer solutions to Translational Oncology Solutions, which includes pharmaceutical and biotechnology companies; and Personalized Oncology, which assists physicians in developing personalized treatment options for their cancer patients. The company was founded by James M. Martell and David Sidransky on June 4, 1985 and is headquartered in Hackensack, NJ.

View Champions Oncology Profile